488 related articles for article (PubMed ID: 11857288)
61. Dexamethasone, high-dose cytarabine, and cisplatin in combination with rituximab as salvage treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.
Mey UJ; Orlopp KS; Flieger D; Strehl JW; Ho AD; Hensel M; Bopp C; Gorschlüter M; Wilhelm M; Birkmann J; Kaiser U; Neubauer A; Florschütz A; Rabe C; Hahn C; Glasmacher AG; Schmidt-Wolf IG
Cancer Invest; 2006 Oct; 24(6):593-600. PubMed ID: 16982464
[TBL] [Abstract][Full Text] [Related]
62. Fludarabine and cytarabine as a sequential infusion regimen for treatment of adults with recurrent, refractory or poor prognosis acute leukemia.
Vidarsson B; Abonour R; Williams EC; Woodson RD; Turman NJ; Kim K; Mosher DF; Wiersma SR; Longo WL
Leuk Lymphoma; 2001 Apr; 41(3-4):321-31. PubMed ID: 11378544
[TBL] [Abstract][Full Text] [Related]
63. Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation.
Visco C; Finotto S; Zambello R; Paolini R; Menin A; Zanotti R; Zaja F; Semenzato G; Pizzolo G; D'Amore ES; Rodeghiero F
J Clin Oncol; 2013 Apr; 31(11):1442-9. PubMed ID: 23401442
[TBL] [Abstract][Full Text] [Related]
64. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
65. Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphoma.
William BM; Allen MS; Loberiza FR; Bociek RG; Bierman PJ; Armitage JO; Vose JM
Biol Blood Marrow Transplant; 2014 Apr; 20(4):536-42. PubMed ID: 24434781
[TBL] [Abstract][Full Text] [Related]
66. [A clinical observation of fludarabine-containing regimens in the treatment of low grade non-Hodgkin's lymphoma].
Lü SQ; Yang JM; Song XM; Chen L; Zhang WP; Ni X; Xu XQ; Wang JM
Zhonghua Zhong Liu Za Zhi; 2007 Sep; 29(9):710-2. PubMed ID: 18246806
[TBL] [Abstract][Full Text] [Related]
67. Dexamethasone, etoposide, ifosfamide, and cisplatin as second-line therapy in patients with aggressive non-Hodgkin's lymphoma.
Haim N; Ben-Shahar M; Faraggi D; Tsuri-Etzioni A; Leviov M; Epelbaum R
Cancer; 1997 Nov; 80(10):1989-96. PubMed ID: 9366303
[TBL] [Abstract][Full Text] [Related]
68. Lomustine (chloroethylnitrosourea [CCNU]), ifosfamide, bleomycin, vincristine, and cisplatin (CIBO-P) is an effective regimen for patients with poor prognostic refractory or multiple disease recurrent aggressive non-Hodgkin lymphoma.
Musolino A; Perrone MA; Michiara M; Delnevo D; Franciosi V; Di Blasio B; Ceci G; Camisa R; Ardizzoni A; Cocconi G
Cancer; 2005 May; 103(10):2109-17. PubMed ID: 15803492
[TBL] [Abstract][Full Text] [Related]
69. E-SHAP: an effective treatment in selected patients with relapsed non-Hodgkin's lymphoma.
Ezzat AA; Khalifa F; Berry J; Khan B; Raja MA; Abdel-Warith A
Ann Oncol; 1994 May; 5(5):453-6. PubMed ID: 8075052
[TBL] [Abstract][Full Text] [Related]
70. Mitoxantrone/high-dose Ara-C and recombinant human GM-CSF in the treatment of refractory non-Hodgkin's lymphoma. A pilot study.
Ho AD; Del Valle F; Engelhard M; Hiddemann W; Rückle H; Schlimok G; Haas R; Thiel E; Andreesen R; Fiedler W
Cancer; 1990 Aug; 66(3):423-30. PubMed ID: 2194641
[TBL] [Abstract][Full Text] [Related]
71. Modified DHAP regimen in the salvage treatment of refractory or relapsed lymphomas.
Kroschinsky F; Röllig D; Riemer B; Kramer M; Ordemann R; Schetelig J; Bornhäuser M; Ehninger G; Hänel M
J Cancer Res Clin Oncol; 2019 Dec; 145(12):3067-3073. PubMed ID: 31563974
[TBL] [Abstract][Full Text] [Related]
72. Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: a consortium for improving survival of lymphoma (CISL) trial.
Park BB; Kim WS; Suh C; Shin DY; Kim JA; Kim HG; Lee WS
Ann Hematol; 2015 Nov; 94(11):1845-51. PubMed ID: 26251158
[TBL] [Abstract][Full Text] [Related]
73. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
74. [Efficacy of DACE regimen on relapsed and refractory non-Hodgkin's lymphoma].
Zhang MZ; Zang WP; Song M; Geng L; Li X; Wang RL
Ai Zheng; 2008 Apr; 27(4):435-7. PubMed ID: 18423133
[TBL] [Abstract][Full Text] [Related]
75. Results of a phase II study of vorinostat in combination with intravenous fludarabine, mitoxantrone, and dexamethasone in patients with relapsed or refractory mantle cell lymphoma: an interim analysis.
Shin DY; Kim SJ; Yoon DH; Park Y; Kong JH; Kim JA; Kim BS; Kim HJ; Won JH; Park SK; Kim WS
Cancer Chemother Pharmacol; 2016 Apr; 77(4):865-73. PubMed ID: 26984211
[TBL] [Abstract][Full Text] [Related]
76. Intensive sequential chemotherapy (ISC 95) with growth factors and blood stem cell support in high-intermediate and high-risk (IPI 2 and IPI 3) aggressive non-Hodgkin's lymphoma: an oligocentric report on 42 patients.
Bouabdallah R; Stoppa AM; Rossi JF; Lepeu G; Coso D; Xerri L; Ladaique P; Chabannon C; Blaise D; Bardou VJ; Alzieu C; Gastaut JA; Maraninchi D
Leukemia; 1999 Jun; 13(6):950-6. PubMed ID: 10360385
[TBL] [Abstract][Full Text] [Related]
77. Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non-Hodgkin's lymphoma.
Chau I; Harries M; Cunningham D; Hill M; Ross PJ; Archer CD; Norman AR; Wotherspoon A; Koh DM; Gill K; Uzzell M; Prior Y; Catovsky D
Br J Haematol; 2003 Mar; 120(6):970-7. PubMed ID: 12648066
[TBL] [Abstract][Full Text] [Related]
78. Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma.
Tam CS; Wolf M; Prince HM; Januszewicz EH; Westerman D; Lin KI; Carney D; Seymour JF
Cancer; 2006 Jun; 106(11):2412-20. PubMed ID: 16649223
[TBL] [Abstract][Full Text] [Related]
79. Phase II study of paclitaxel in combination with mitoxantrone and ifosfamide/mesna for patients with relapsed or refractory non-Hodgkin's lymphoma after failure to cytarabine/cisplatin combination.
Romaguera JE; Rodriguez MA; Hagemeister FB; McLaughlin P; Rodriguez J; Preti A; Younes A; Sarris AH; Cabanillas F
Invest New Drugs; 1999; 17(2):187-92. PubMed ID: 10638491
[TBL] [Abstract][Full Text] [Related]
80. Factors which predict unsuccessful mobilisation of peripheral blood progenitor cells following G-CSF alone in patients with non-Hodgkin's lymphoma.
Micallef IN; Apostolidis J; Rohatiner AZ; Wiggins C; Crawley CR; Foran JM; Leonhardt M; Bradburn M; Okukenu E; Salam A; Matthews J; Cavenagh JD; Gupta RK; Lister TA
Hematol J; 2000; 1(6):367-73. PubMed ID: 11920216
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
